Suggestions
Seemant Jauhari
Managing Partner at HealthXCapital
Seemant Jauhari is an experienced healthcare executive and investor who recently joined Jungle Ventures as a Partner Healthcare in August 2023.1 Prior to this, he was the Managing Partner at HealthXCapital, a Singapore-based venture firm focused on innovative healthcare investments.12
Career Highlights
Healthcare Investment Experience:: Seemant founded and led HealthXCapital, which was the first dedicated early-stage healthcare venture capital firm in South and Southeast Asia.45 At HealthXCapital, he focused on investments in devices, diagnostics, and digital health applications, with an emphasis on access and affordability for emerging markets.1
Corporate Experience:: Before his venture capital career, Seemant held several leadership positions in the healthcare industry:
- CEO of Apollo Research & Innovations at Apollo Hospitals (2014-2017)1
- CEO of Apollo Hospitals Education & Research Foundation (2010-2014)1
He also gained diverse experience in:
- Business consulting at Ernst & Young
- Strategy and transformation at Nokia Siemens Networks
- IT consulting at Tata Consultancy Services13
Education
Seemant has a strong educational background:
- MBA from the Indian School of Business
- Bachelor of Engineering from Birla Institute of Technology, Mesra
- Executive education from UC Berkeley's Haas School of Business and Tel Aviv University13
Current Roles
As of September 2024, Seemant holds several positions:
- Partner Healthcare at Jungle Ventures (since August 2023)
- Board Member at Medfin (since November 2020)
- Board Member at Homage (since May 2018)1
Seemant Jauhari brings over 22 years of experience in healthcare innovation, business consulting, and strategy to his current role at Jungle Ventures.3 His expertise in healthcare investments and deep industry knowledge make him a valuable asset in the healthcare venture capital space.
Highlights
What a rousing start to 2024...just concluded the 42nd JP Morgan Healthcare conference in San Francisco! Terrific set of events, presentations, people discussing all things healthcare. Several learnings off which listing a few key takeaways:
-
Jamie Dimon's key note was a eye opener highlighting the US economy is in the Goldilocks economic scenario state akin to the 1970s with stagnant growth and high inflation...it may not be a soft landing after all! Recession is a possibility. Covd money will run out this year whilst interest rates are still high.
-
That said healthcare saw some hectic activity to kick off the year with companies announcing over $6.4 billion in health care deals during the JPM conference setting the tone for 2024. E.g: Boston Scientific acquiring Axonis for $3.7Bn
-
Biotech is back with a surge of deals after a very quiet period 2022-23
-
Potential for AI and GenAi in life sciences and healthcare efficiencies continued to be a topic for discussion. Bound to be more investments in this space but its early days
-Focus on cardio-metabolic is back; Omada health shared it now serves 20M americans with a 90% retention...thats an important signal for digital health platforms that there are no shortcuts ... B2B2C , outcomes, payor participation holds the key.
-
Key to 2024 will be to maintain valuations within a range and wait for the next ipo window to unlock capital
-
Most pharma felt valuations were over heated; Reduce R&D costs will drive more spin offs with creative JVs/deals enabling more transactions
-
R&D expense is increasing, revenue is dropping, sg&a is static - AI, Gen ai or something else needs to bring in efficiencies.
-
Care navigation is back in focus
-
De-risked assets (multiple product) biotechs will attract capital with higher premiums
-
Biggest surprise for 2024 could be increase in valuations as good quality companies come out to raise more capital after the lull -Productivity and efficiency will be in focus esp with labor and wage inflation
-
Focus on free cash flow
-
Focus change from Growth driven demand management to Margin management ; Balance both -Revenue cycle mgmt, life sciences and payor services back in focus -Consolidation will happen driving more deals -Deal momentum will continue in 2024 higher than 2023 Thank you JPMorgan Chase & Co. EY Bain & Company McDermott Will & Emery FINN Partners SVB PitchBook Eight Roads Baker McKenzie McKinsey & Company KPMG US Goodwin for having me participate, learn, network. Gratitude!
Overall a lot of learning, positive beginning to 2024 and look forward to an exciting year with more innovations and more deals pushing forward in what is one of the most resilient sectors on the planet! Happy 2024! #JPM #healthcare #sanfrancisco #2024
Thrilled to have 4 of our portfolio companies recognized in Top 100 HealthTech Companies in South & Southeast Asia by HolonIQ!
Congratulations to the Founders & Teams at Homage MiyaHealth THB & StanPlus
Being one of the very few healthcare focused early-stage funds in the region its a great honor to work with world class teams to build category leaders.
You can access the full articles here: South Asia Healthtech Top 100 - https://lnkd.in/gBmkvHFK
SouthEast Asia Healthtech Top 50 - https://lnkd.in/gUci7Ekc #healthcare #leaders #founders Gillian Tee Ramesh Rajentheran Akansh Khurana Prabhdeep Singh Jimit Patel Zubin Daruwalla Dr Prem Pillay FACS(USA) Daniel Kraft, MD Arda Minocherhomjee Priyanka Bajpai Pranav Rastogi Jayesh Parekh Ashish Oza Audrey Lok Devanathan Raghunathan PhD MBA Gabriel SIM Hajime Sato Nozomi Okada Prabhu Goel Ram Reddy Ewan Davis Kotaro Ujihara Krishnan Akhileswaran Amit Anand Anurag Srivastava Jungle Ventures
